ONCOTICE 2-8 X 10(8) UFC POLVO PARA SUSPENSION INTRAVESICAL

( ARTG ) Onco TICE is used as a treatment of primary or recurrent carcinomain situ of the urinary bladder. Onco TICE is also used after transurethral resection for the prevention or recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage TA or T1 - grades 1, 2, or 3) INDICATIONS AS AT 3 OCTOBER 2001: OncoTICE is used as a treatment ofthe urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carinoma of the urinary bladder (viz papillary carcinoma stage TA (grade 2 or 3) or T1 (grade 1, 2, or 3). OncoTICE is only recommended for stage TA grade 1 tumours, when there is judged to be a high risk of tumour recurrence is considered likely. INIDICATIONS AS AT 24 APRIL 2002: OncoTICE is used as a treatment of primary of recurrent carcinoma in situ (CIS) of the urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage Ta (grade 2 or 3) or T1 (grade 1, 2, or 3). OncoTICE is only reccommended for stage Ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence.